Dermatomyositis: Diagnosis, evaluation and management

Minerva Medica

Volumn , Issue 3, 2002, Pages 157-167

  Callen, J P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Dermatomyositis, classification; Dermatomyositis, diagnosis; Dermatomyositis, drug therapy

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; QUINIDINE;

CANCER RISK; CLINICAL EXAMINATION; CLINICAL FEATURE; DERMADROME; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; HUMAN; REVIEW; PARANEOPLASTIC SYNDROME; PATHOLOGY;

DERMATOMYOSITIS; HUMANS; PARANEOPLASTIC SYNDROMES;

EID: 0035983673     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Dermatomyositis
2. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy
3. Dermatomyositis and polymyositis
4. Polymyositis and dermatomyositis
5. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
6. Dermatomyositis: An overview of issues of interest to dermatologists
7. Dermatomyositis and drugs
8. Cutaneous photosensitivity in dermatomyositis
9. Photodermatitis in a 6-year-old child
10. Recurrent photosensitive dermatitis preceding juvenile dermatomyositis
11. A young woman with a photosensitive pruritic rash on her face and upper trunk
12. Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed
13. Dermatomyositis presenting as plaque-like mucinosis
14. Centripetal flagellate erythema: A cutaneous manifestation associated with dermatomyositis
15. Vesiculo-bullous dermatomyositis
16. Dermatomyositis with a pityriasis rubra pilaris-like eruption: A little-known distinctive cutaneous manifestation of dermatomyositis
17. Gingival telangiectases. An underappreciated physical sign of juvenile dermatomyositis
18. Angiokeratomas in juvenile dermatomyositis
19. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: DM siné myositis?
20. Cutaneous changes of dermatomyositis precede muscle weakness
21. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids
22. Amyopathic dermatomyositis: A review by the Italian group of immunodermatology
23. Idiopathic iInflammatory diseases of muscle
24. Extramuscular manifestations in idiopathic inflammatory myopathies
25. Pulmonary involvement in polymyositis and in dermatomyositis
26. Cardiac manifestations in dermato-polymyositis
27. Risk of cancer in patients with dermatomyositis or polymyositis
28. Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark
29. Elevated cancer incidence in patients with dermatomyositis: A population based study
30. Increased incidence of specific cancer types in dermatomyositis and polymyositis: Combined papulation data from 3 Nordic countries
31. Ovarian cancer in patients with dermatomyositis
32. Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases
33. Influence of age on characteristics of polymyositis and dermatomyositis in adults
34. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study
35. An update on juvenile dermatomyositis
36. Medium- and long-tern functional outcomes in a multicenter cohort of children with juvenile dermatomyositis
37. TNFα-308A allele in juvenile dermatomyositis
38. Hydroxyurea dermopathy. A unique lichenoid eruption complicating long-term therapy with hydroxyurea
39. Pseudo-dermatomyositis as a complication of hydroxyurea therapy
40. MRI in inflammatory myopathies
41. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups
42. Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis
43. The value of malignancy evaluation in patients with dermatomyositis
44. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases
45. Chlorambucil: An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis
46. Update on therapy for refracto-dermatomyositis and polymyositis
47. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis
48. Intermittent high dose intravenous methylprednisolone (IV pulse) prevents calcinosis and shortens disease course in juvenile dermatomyositis (JDMS)
49. Clinical characteristics and outcome of idiopathic inflammatory myositis (IIM) in childhood: A 2 year follow-up
50. Treatment of refractory myositis. A randomized crossover study of 2 new cytotoxic regimens
51. Anti-TNF-blockade with infliximab (remicade) in polymyositis and dermatomyositis
52. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis
53. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
54. Intravenous immunoglobulin therapy for juvenile dermatomyositis: Efficacy and safety
55. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine
56. Low-dose methotrexate administered weekly in an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis
57. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate
58. Treatment of calcinosis in juvenile dermatomyositis with probenecid: The role of phosphorus metabolism in the development of calcifications
59. Regression of calcinosis during Diltiazem treatment of juvenile dermatomyositis
60. Polymyositis and dermatomyositis: Short term and longterm outcome, and predictive factors of prognosis